Against 307 pneumococci of various resistotypes, dalbavancin MICs were 0.008 to 0.125 g/ml. All strains were susceptible to vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin. Dalbavancin at 2؋ MIC was bactericidal against all 10 pneumococci tested after 24 h. Vancomycin and teicoplanin killed 10 and 8 strains, respectively, at 2؋ MIC after 24 h.
crodilution MICs (18) with dry-format trays (TREK Diagnostics, Cleveland, OH) were used. Standard quality control strains (18) were included in each run. Strains used for timekill studies also had MICs determined using the broth macrodilution method (18) .
For time-kills, previously reported techniques were used (19, 24) . Only initial inocula of 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml were acceptable (19, 24) . Viability counts were as described previously, and colony counts were performed on plates yielding 30 to 300 colonies. The lower limit of sensitivity of colony counts was 300 CFU/ml (19, 24) . Time-kill assays were analyzed by determining the number of strains with a ⌬log 10 CFU/milliliter of Ϫ1, Ϫ2, and Ϫ3 at 3, 6, 12, and 24 h compared to counts at time zero. Bactericidal activity was considered a reduction of the original inoculum by Ն3 log 10 CFU/ml (99.9%) (19, 24) . MICs are presented in Table 1 . Dalbavancin had potent activity against all pneumococci, with MICs of 0.008 to 0.125 g/ml. Vancomycin and teicoplanin were potent, with MICs of 0.03 to 0.5 g/ml and 0.03 to 0.25 g/ml, respectively. Linezolid inhibited all strains at Յ2.0 g/ml, and quinupristin-dalfopristin inhibited all strains at Յ1.0 g/ml. ␤-Lactam and azithromycin MICs paralleled those of penicillin G. Except for 30 strains chosen for their quinolone resistance phenotype, strains were susceptible to levofloxacin, with MICs of Յ2.0 g/ml.
Broth macrodilution MICs of strains tested by time-kill are listed in Table 2 , and time-kills are listed in Table 3 . Dalbavancin was bactericidal to the extent of at least 3 logs at 2ϫ MIC after 24 h against all 10 strains and against 8 strains at MIC. By comparison, vancomycin and teicoplanin were bactericidal by 3 logs at 2ϫ MIC after 24 h against 10 and 8 strains, respectively. Linezolid was mainly bacteriostatic and quinupristin-dalfopristin was bactericidal against all 10 strains at 2ϫ MIC after 24 h, with significant killing at earlier periods. ␤-Lactams were bactericidal against 9 or 10 strains at 2ϫ MIC after 24 h. Levofloxacin was bactericidal against all eight quinolone-susceptible strains at 2ϫ MIC after 24 h, and azithromycin was bactericidal against five of six macrolide-susceptible strains at 2ϫ MIC after 24 h.
Dalbavancin is a semisynthetic derivative of the teicoplaninlike glycopeptide A40926 and is more active in vitro against staphylococci than teicoplanin and vancomycin. Against streptococci, dalbavancin has activity comparable to teicoplanin but better than vancomycin (1, 2, 13, 15, 23) . In a study of Ͼ6,000 isolates, Streit et al., using CLSI broth microdilution methodology, showed excellent dalbavancin activity against all grampositives except vanA enterococci (23) , with a MIC range against 1,396 drug-susceptible and -resistant pneumococci of Յ0.015 to 0.25 g/ml. Similarly, in our study all strains tested had dalbavancin MICs between 0.008 and 0.125 g/ml. Our vancomycin agar dilution MICs were very similar to those reported by Streit et al. in broth, with 50% minimum inhibitory concentration (MIC 50 ) and MIC 90 s of 0.25 and 0.5 g/ml, respectively, by both methods. Jones and coworkers demonstrated bactericidal activity of dalbavancin against S. pneumoniae ATCC 49619 at 4ϫ MIC after 24 h, but exact meth- 8  2  2  8  3  2  8  8  2  8  8  8  2ϫ MIC  8  2  1  8  2  2  8  8  2  8  8  8  MIC  6  2  0  8  2  1  8  7  2  8  7 odology was not provided (13) . In our study, dalbavancin kinetics were similar to those of vancomycin and teicoplanin, i.e., relatively slow compared to those of ␤-lactams and levofloxacin. We have found dalbavancin to be bactericidal after 24 h at 2ϫ MIC against Staphylococcus aureus strains, including the Hershey vancomycin-resistant S. aureus, with cidality against eight strains at MIC (15) . MICs and time-kills for other compounds were consistent with previous studies (3, 5, 9, 11, 12, 16, 20, 22, 24) . Against anaerobic gram-positive species and corynebacteria and using agar dilution, dalbavancin had MICs of Յ2.0 g/ml against all species except Clostridium clostridioforme and lactobacilli (8) . Dalbavancin agar MICs are higher than those in broth for reasons that are under investigation (8, 15) . However, our results of broth macrodilution MIC assays in strains tested by time-kill were similar to those obtained using prepared dry-format trays.
Due to its half-life of ca. 8 days, dalbavancin is under investigation as a once-weekly-dose drug (7) . A recent study has shown that two doses of dalbavancin administered 1 week apart is effective in treatment of complicated gram-positive skin and soft-tissue infections (21) , and Lefort et al. have reported that a single dose of dalbavancin was active against S. aureus with or without reduced glycopeptide susceptibility in an adult rabbit endocarditis model (14) .
Our results indicate a potential place for dalbavancin in therapy of drug-susceptible and -resistant pneumococcal infections. Clinical trials will be necessary in order to validate this hypothesis.
